Sol-Gel Technologies (SLGL) Income from Continuing Operations (2017 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Income from Continuing Operations came in at 3855000.0 in Q1 2026, down 57.49% year-on-year from 9069000.0 in Q1 2025, and up 106.23% on a QoQ basis from 61915000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 10 years of Income from Continuing Operations data on file, last reported at 3855000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 57.49% year-over-year to 3855000.0 in Q1 2026; TTM through Mar 2026 was 53118000.0, a 15.41% decrease from a year earlier, with the FY2025 full-year figure at 66042000.0, down 6.86% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3855000.0, up from 61915000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for SLGL reached as high as 11230000.0 in Q2 2025 and fell as low as 61915000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 11507705.88 across 5 years, with a median of 828000.0 in 2024.
- Across the five-year window, Income from Continuing Operations slumped 1509.72% in 2023 and soared 591.5% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 50899000.0 in 2022, then slipped by 4.75% to 53319000.0 in 2023, then retreated by 4.82% to 55889000.0 in 2024, then decreased by 10.78% to 61915000.0 in 2025, then soared by 106.23% to 3855000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 3855000.0 in Q1 2026, 61915000.0 in Q4 2025, and 6288000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Sol-Gel Technologies | 234.04 Mn | 223.91 Mn | - | 3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | -61.92 Mn |
| Sep 30, 2025 | -6.29 Mn |
| Jun 30, 2025 | 11.23 Mn |
| Mar 31, 2025 | 9.07 Mn |
| Dec 31, 2024 | -55.89 Mn |
| Sep 30, 2024 | -828,000.00 |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | -53.32 Mn |
| Sep 30, 2023 | -6.31 Mn |
| Jun 30, 2023 | -6.53 Mn |
| Mar 31, 2023 | 11.06 Mn |
| Dec 31, 2022 | -50.90 Mn |
| Sep 30, 2022 | -3.63 Mn |
| Jun 30, 2022 | 463,000.00 |
| Mar 31, 2022 | 5.95 Mn |
| Dec 31, 2021 | 13.55 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 8.04 Mn |